Contras agent having an imaging agent coupled to viable granulocytes for use in magnetic resonance imaging of abscess and a method of preparing and using same

• US 5,045,304 A
• Filed: 08/31/1988
• Issued: 09/03/1991
• Est. Priority Date: 08/31/1988
• Status: Expired due to Fees

• Current Assignee: Wayne State University
• Original Assignee: Wayne State University
• Inventors: Schneider, David R., Bis, Kostaki G.
• Primary Examiner(s): Raymond, Richard L.
• Assistant Examiner(s): Hollinden, Gary E.
• Application Number:
  US07/238,870
• Time in Patent Office: 1,098 Days
• Field of Search: 424/9, 424/647, 424/648, 436/173, 128/653, 128/653 AF, 128/653 CA, 128/654, 435/2
• US Class Current: 424/9.32
• CPC Class Codes: A61K 49/06 Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
• CPC Class Codes: G01R 33/5601 involving use of a contrast agent for contrast manipulation, e.g. a paramagnetic, super-paramagnetic, ferromagnetic or hyperpolarised contrast agent
• CPC Class Codes: Y10T 436/24 Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Abstract

A method and contrast agent for magnetic resonance imaging (MRI) of abscess. Granulocytes are separated from whole blood and incubated with an imaging vehicle such as magnetite. The granulocytes encapsulate the imaging vehicle and are suspended in an intravascularly administrable carrier to form the contrast agent. The contrast agent is highly specific for MRI of abscess.

Claims

1. A method of preparing and using contrast agent in magnetic resonance imaging abscesses in a patient comprising the steps of:

mixing a specific number of viable granulocytes with an aqueous solution of a metallic imaging agent in which said imaging agent binds to and is subsequently incorporated into the granulocytes incubating said aqueous solution to encapsulate said imaging agent in said granulocytes to form labeled granulocytes;

separating said labeled granulocytes from said solution;

suspending said labeled granulocytes in an intravascularly administerable carrier to form said contrast agent;

administering a diagnostically effective amount of said contrast agent by intravenous infusion to said patient; and

subjecting said patient to examination by magnetic resonance imaging.

2. The method of claim 1 wherein said separating step further comprises attracting said labelled granulocytes from said aqueous solution with a pole magnet.

3. The method of claim 1 further comprising after the separating step, the step of washing the labelled granulocytes with a physiologic buffer.

4. The method of claim 1 in which said imaging agent is a ferromagnetic metal or non-toxic salt thereof.

5. The method of claim 1 in which said imaging agent is a paramagnetic metal or non-toxic salt thereof.

6. The method of claim 1 in which said imaging agent is a superparamagnetic metal or non-toxic salt thereof.

7. The method of claim 1 in which said imaging agent is magnetite;

Fe₂ O₃.FeO.

8. The method of claim 1 in which the incubating step further comprises bubbling O₂ through said aqueous solution.

9. The method of claim 1 in which the imaging agent has the formula F₂ O₃.XO, where X is one of the group consisting of para-magnetic and ferro-magnetic material.

10. A contrast reagent for MRI of abscesses, said reagent comprising:

a suspension of labelled granulocytes in an intravascularly adminstrable carrier, said granulocytes binding to and subsequently incorporating within a diagnostically effective amount of an imaging agent, said agent having the formula Fe₂ O₃.XO where X is one of the group consisting of para-magnetic and ferro-magnetic materials.

11. The contrast agent of claim 10 wherein said imaging agent is magnetite;

Fe₂ O₃.FeO.

12. The contrast agent of claim 10 wherein said intravascularly adminsterable carrier is plasma.